Eli Samaha - 23 Sep 2026 Form 4 Insider Report for Theravance Biopharma, Inc.

SEC form
4
Accepted by SEC
16 Nov 2026, 10:53:38 UTC
Prior SEC filing
08 Jul 2026
Next SEC filing
02 Oct 2026
Source filing
View source filing
Filing notes and source

Key filing fact

Eli Samaha filed Form 4 for Theravance Biopharma, Inc. on 16 Nov 2026.

Key facts

  • This page summarizes Eli Samaha's Form 4 filing for Theravance Biopharma, Inc..
  • 1 reported transaction and 0 derivative rows are listed below.
  • Accepted by SEC: 16 Nov 2026, 10:53.

Change

  • Previous filing in this sequence was filed on 08 Jul 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001877589 Primary reporting owner

Samaha Eli

Relationship
10%+ Owner

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

No ticker transaction

COM

Other

Transaction value
Shares
-9,167,489
Change %
-100%
Price
$17.00*
Shares after
0
Date
23 Sep 2026
Ownership
See Footnotes
Footnotes
F1, F2
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.

Footnote F2

These shares are held by funds managed by Madison Avenue Partners, LP. The Reporting Person is the non-member manager of Madison Avenue GP, LLC, the managing member of EMAI Management, LLC, and the majority owner of Caraway Jackson Investments LLC. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of the pecuniary interest of the Reporting Person therein. The filing of this statement shall not be deemed an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the Reporting Person is the beneficial owner of such securities.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .